The markets opened flat with the Dow adding 5 points to 19,103 as crude oil prices fell. Nasdaq rose 14 points 5,383.
On the upside
Genetic Technologies (Nasdaq: GENE) entered an exclusive worldwide license agreement with the University of Melbourne to develop and commercialize a novel colorectal cancer risk assessment test.
The New York State Department of Health conditionally approved CombiMatrix's (Nasdaq: CBMX) pre-implantation genetic screening by next generation sequencing.
Acasti Pharma (Nasdaq: ACST) named Linda O'Keefe to the position of chief financial officer.
On the downside
The Food and Drug Administration rejected Amicus Therapeutics' (Nasdaq: FOLD) request for accelerated approval of its Fabry disease treatment migalastat.
Nivalis Therapeutics (Nasdaq: NVLS) reported disappointing results from a Phase 2 clinical trial of its cystic fibrosis treatment cavosonstat.
Investors locked in profits on PhaseRx (Nasdaq: PZRX).
In the broad market, advancing issues outpaced decliners by a margin of nearly 10 to 9 on the NYSE and by more than 9 to 7 on Nasdaq. The broader S&P 500 added a point to 2,203. Bitcoin eased a fraction to $731.
